279 related articles for article (PubMed ID: 24737887)
1. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.
Schmit F; Utermark T; Zhang S; Wang Q; Von T; Roberts TM; Zhao JJ
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6395-400. PubMed ID: 24737887
[TBL] [Abstract][Full Text] [Related]
2. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
3. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
[TBL] [Abstract][Full Text] [Related]
4. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
Utermark T; Schmit F; Lee SH; Gao X; Schaffhausen BS; Roberts TM
J Virol; 2014 Sep; 88(18):10673-9. PubMed ID: 24991009
[TBL] [Abstract][Full Text] [Related]
5. Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas.
Xie S; Ni J; McFaline-Figueroa JR; Wang Y; Bronson RT; Ligon KL; Wen PY; Roberts TM; Zhao JJ
Cell Rep; 2020 Sep; 32(13):108196. PubMed ID: 32997991
[TBL] [Abstract][Full Text] [Related]
6. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
Weigelt B; Warne PH; Lambros MB; Reis-Filho JS; Downward J
Clin Cancer Res; 2013 Jul; 19(13):3533-44. PubMed ID: 23674493
[TBL] [Abstract][Full Text] [Related]
7. PTEN-deficient cancers depend on PIK3CB.
Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
[TBL] [Abstract][Full Text] [Related]
8. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.
Jiang X; Chen S; Asara JM; Balk SP
J Biol Chem; 2010 May; 285(20):14980-14989. PubMed ID: 20231295
[TBL] [Abstract][Full Text] [Related]
9. Should individual PI3 kinase isoforms be targeted in cancer?
Jia S; Roberts TM; Zhao JJ
Curr Opin Cell Biol; 2009 Apr; 21(2):199-208. PubMed ID: 19200708
[TBL] [Abstract][Full Text] [Related]
10. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
11. CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells.
Zhang J; Gao X; Schmit F; Adelmant G; Eck MJ; Marto JA; Zhao JJ; Roberts TM
Cell Rep; 2017 Jul; 20(3):549-557. PubMed ID: 28723560
[TBL] [Abstract][Full Text] [Related]
12. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.
Ni J; Liu Q; Xie S; Carlson C; Von T; Vogel K; Riddle S; Benes C; Eck M; Roberts T; Gray N; Zhao J
Cancer Discov; 2012 May; 2(5):425-33. PubMed ID: 22588880
[TBL] [Abstract][Full Text] [Related]
14. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
15. PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
Wu CY; Carpenter ES; Takeuchi KK; Halbrook CJ; Peverley LV; Bien H; Hall JC; DelGiorno KE; Pal D; Song Y; Shi C; Lin RZ; Crawford HC
Gastroenterology; 2014 Dec; 147(6):1405-16.e7. PubMed ID: 25311989
[TBL] [Abstract][Full Text] [Related]
16. Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers.
Mao N; Zhang Z; Lee YS; Choi D; Rivera AA; Li D; Lee C; Haywood S; Chen X; Chang Q; Xu G; Chen HA; de Stanchina E; Sawyers C; Rosen N; Hsieh AC; Chen Y; Carver BS
Nat Commun; 2021 Aug; 12(1):5053. PubMed ID: 34417459
[TBL] [Abstract][Full Text] [Related]
17. Class I Phosphoinositide 3-Kinase
Mazloumi Gavgani F; Smith Arnesen V; Jacobsen RG; Krakstad C; Hoivik EA; Lewis AE
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544563
[TBL] [Abstract][Full Text] [Related]
18. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.
Lee SH; Poulogiannis G; Pyne S; Jia S; Zou L; Signoretti S; Loda M; Cantley LC; Roberts TM
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):11002-7. PubMed ID: 20534477
[TBL] [Abstract][Full Text] [Related]
19. Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines.
Juvin V; Malek M; Anderson KE; Dion C; Chessa T; Lecureuil C; Ferguson GJ; Cosulich S; Hawkins PT; Stephens LR
PLoS One; 2013; 8(10):e75045. PubMed ID: 24124465
[TBL] [Abstract][Full Text] [Related]
20. Regulation of CD38 expression in human airway smooth muscle cells: role of class I phosphatidylinositol 3 kinases.
Jude JA; Tirumurugaan KG; Kang BN; Panettieri RA; Walseth TF; Kannan MS
Am J Respir Cell Mol Biol; 2012 Oct; 47(4):427-35. PubMed ID: 22556157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
